期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Simulation of optimal dose regimens of photoactivated curcumin for antimicrobial resistance pneumonia in COVID-19 patients:A modeling approach
1
作者 teerachat saeheng Kesara Na-Bangchang 《Infectious Disease Modelling》 CSCD 2023年第3期783-793,共11页
Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current... Background:Secondary antimicrobial resistance bacterial(AMR)pneumonia could lead to an increase in mortality in COVID-19 patients,particularly of geriatric patients with underlying diseases.The comedication of current medicines for AMR pneumonia with corticosteroids may lead to suboptimal treatment or toxicities due to drug-drug interactions(DDIs).Objective:This study aimed to propose new promising dosage regimens of photoactivated curcumin when co-administered with corticosteroids for the treatment of antimicrobial resistance(AMR)pneumonia in COVID-19 patients.Methods:A whole-body physiologically-based pharmacokinetic(PBPK)with the simplified lung compartments model was built and verified following standard model verification(absolute average-folding error or AAFEs).The pharmacokinetic properties of photo-activated were assumed to be similar to curcumin due to minor changes in physiochemical properties of compound by photoactivation.The acceptable AAFEs values were within 2-fold.The verified model was used to simulate new regimens for different formulations of photoactivated curcumin.Results:The AAFEs was 1.12-fold.Original formulation(120 mg once-daily dose)or new intramuscular nano-formulation(100 mg with a release rate of 10/h given every 7 days)is suitable for outpatients with MRSA pneumonia to improve patient adherence.New intravenous formulation(2000 mg twice-daily doses)is for hospitalized patients with both MRSA and VRSA pneumonia.Conclusion:The PBPK models,in conjunction with MIC and applied physiological changes in COVID-19 patients,is a potential tool to predict optimal dosage regimens of photo-activated curcumin for the treatment of co-infected AMR pneumonia in COVID-19 patients.Each formulation is appropriate for different patient conditions and pathogens. 展开更多
关键词 PBPK MRSA VRSA Photoactivated-curcumin COVID-19 PNEUMONIA Antimicrobial-resistance bacteria Pharmacokinetics
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部